RE:rbcfrom the q and a portion of the conference call . it was stated
Matthew coffey
Thanks John , i'm going to push tom under the bus on this one . and its interesting because i'm not sure if you saw the destiny six results that came out yesterday because that certainly has a bearing on what fortunately we were able to flag with the type c meeting with the agency and then very loosely we can talk about comparable studies on that . i think would be basically we've modeled on, if there's any questions at that time . we'd behappy to help out .
I'm surprised many didnt question what matt said .
Oncolytics Biotech, Inc. (ONCY) Q1 2024 Earnings Call Transcript | Seeking Alpha
you have to click on the link at the bottom for the q and a
here is a link about destiny 6
Destiny-Breast06 Results Offer New Hope for Patients With HR-Positive, HER2-Low Metastatic Breast Cancer (ajmc.com)
from the link
Just 2 months after the results were presented, trastuzumab deruxtecan received a rapid approval to treat HER2-low breast cancer.5